Core Insights - Summit Therapeutics (SMMT) reported a second-quarter 2025 loss per share of $0.76, significantly wider than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.09 in the same period last year [1][7] - The company currently has no marketed products, resulting in no recorded revenues for the quarter [2] - Year-to-date, SMMT shares have increased by 58.3%, outperforming the industry average increase of 5.3% [2] Financial Performance - Adjusted research and development expenses reached $79.4 million, a 190.8% increase year-over-year, primarily due to higher costs for expanding clinical studies for ivonescimab [4] - Adjusted general and administrative expenses rose by 64.5% year-over-year to $10.2 million, driven by costs associated with developing infrastructure for ivonescimab [4] - As of June 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $297.9 million, down from $361.3 million as of March 31, 2025 [5] Pipeline Developments - Summit's only pipeline drug, ivonescimab, is a first-in-class bispecific antibody targeting PD-1 and VEGF, currently undergoing three late-stage studies for non-small cell lung cancer (NSCLC) [8] - The phase III HARMONi study showed that ivonescimab plus chemotherapy reduced the risk of disease progression by 48% compared to chemotherapy alone, but did not achieve statistically significant overall survival benefits [9][10] - The company plans to file for approval of the ivonescimab-chemo combination for previously treated EGFR-mutated NSCLC, pending further discussions with the FDA regarding the need for statistically significant overall survival benefits [10] Recent Study Results - Positive results were reported from the Akeso-sponsored phase III HARMONi-6 study, where ivonescimab plus chemotherapy showed significant improvement in progression-free survival compared to BeiGene's PD-1 inhibitor [11] - The HARMONi-3 study is evaluating ivonescimab against Merck's Keytruda in first-line metastatic NSCLC patients [12] - The HARMONi-2 study previously demonstrated that ivonescimab outperformed Keytruda in patients with positive PD-L1 expression [13] Collaborations and Approvals - Akeso has secured approval for ivonescimab in a second indication for front-line PD-L1 positive advanced NSCLC based on HARMONi-2 results [14] - Summit has entered clinical trial collaborations with Pfizer and Revolution Medicines to evaluate ivonescimab in combination with their drugs across various solid tumor settings [15]

Financial Performance & Partnerships - Recognized approximately $75 million in 2025, including around $45 million from partnership-related cash milestones and option exercise fees, which significantly reduced net operating cash burn in the first half of 2025 compared to the first half of 2024[12] - Milestone, option exercise, and related deferred revenue of $45.8 million recognized in 2Q 2025 from BeOne and BMS[16, 17] - Potential future milestone payments from existing partnerships could reach up to $6.1278 billion, with royalty rates varying from low single-digit percentages to 20% depending on the partner and therapeutic indication[13] - Cash, cash equivalents, and marketable securities totaled $324.2 million in 2Q 2025, an increase of $9.2 million year-to-date, benefiting from milestone revenues and favorable working capital movements[16, 17] Clinical Development Updates - Investigational New Drug (IND) application cleared for ZW251, with first-in-human studies planned to start in 2025[11, 12, 47] - Phase 2 trial initiated to evaluate zanidatamab in HER2+ neoadjuvant and adjuvant breast cancer[12] - Bristol Myers Squibb collaboration progresses with a $7.5 million option exercise payment to Zymeworks[12] - ZW171: Global Phase 1 study in MSLN-Expressing Solid Tumors (NCT06523803) is an open-label, FIH, dose-escalation study (N~160)[19] - ZW191: Global Phase 1 Study in FRα-Expressing Solid Tumors (NCT06555744) is an open-label, FIH, dose-escalation study (N~145)[24] Zanidatamab Regulatory & Clinical Progress - NMPA granted BeOne conditional approval of zanidatamab in China for BTC, resulting in a $20 million payment to Zymeworks[12] - EMA granted conditional marketing approval of zanidatamab in Europe for BTC, expanding patient access and potential future royalties payable to Zymeworks[12, 47] - Jazz presented encouraging overall survival (OS) data for zanidatamab in 1L HER2+ GEA at the ASCO Annual Congress, showing a median OS of 36.5 months[12]

Financial Data and Key Metrics Changes - Revenue reached $1.3 billion in Q2 2025, representing a 42% year-on-year growth [5][17] - GAAP earnings per ADS grew by $2 compared to Q2 of the previous year [5] - Free cash flow generated in Q2 was $220 million, an increase of over $400 million year-on-year [5] - Gross margin improved to approximately 87% from 85% in the prior quarter [21] - Non-GAAP net income reached $253 million, reflecting an increase of $230 million compared to the previous year [23] Business Line Data and Key Metrics Changes - Brukinza global revenues were $950 million, growing 49% year-on-year, driven by strong performance across all geographies [17] - Tovembra reported a 22% increase in revenue, reflecting continued market leadership in China [19] - In-licensed products showed continued strength, growing 27% year-on-year [19] Market Data and Key Metrics Changes - The US market generated $685 million with a year-on-year growth of 43% [20] - China revenue totaled $429 million, a 23% increase [20] - Europe contributed $152 million with 87% year-on-year growth [20] - Rest of world markets grew by 168% driven by market expansions and new launches [20] Company Strategy and Development Direction - The company aims to maintain leadership in the hematology franchise and expand its solid tumor pipeline [6][15] - Plans to combine assets in multiple phase three trials to improve outcomes for CLL patients [15] - The company is focused on serial innovation in CLL and aims to build a deep pipeline across various disease areas [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term market leadership for Brukinza despite competitive pricing pressures [18] - The company anticipates stable pricing for the remainder of the year [46] - Future impacts from potential US tariffs are expected to be manageable within the context of the P&L [73] Other Important Information - The company is preparing for the initial global approval of Sonro and anticipates pivotal data for its BTK CDAC by 2026 [15] - The tablet formulation of Brukinza is expected to achieve a lower cost of goods and improve patient convenience [24] Q&A Session Summary Question: Update on Brukinza's US net pricing and inventory changes - Management anticipates stable pricing for the remainder of the year and has no significant inventory levels to comment on [46][47] Question: Reaction to Bruin CLL 314 data for PERTO versus IMBRUVICA - Management noted that the OR superiority was not formally tested and emphasized the importance of PFS data [48][49] Question: Delay in starting the second line phase three trial for CDK4 - Management stated that the delay is modest and aims to let data mature for better dose level selection [53] Question: Impact of US tariffs on gross margin - Management indicated that current guidance contemplates known tariffs and that impacts have been mitigated through supply chain strategies [73] Question: Specifics on access to Brukinza and revenue mix - Management confirmed that Brukinza continues to be listed on all Medicare Part D formularies and access is strong [99][100]

Financial Data and Key Metrics Changes - Revenue for Q2 reached $1.3 billion, representing a 42% year-on-year growth [4][16] - GAAP earnings per ADS increased by $2 compared to Q2 of the previous year [4] - Free cash flow generated in Q2 was $220 million, an increase of over $400 million compared to last year [4] Business Line Data and Key Metrics Changes - Brukinza's global revenues were $950 million, growing 49% year-on-year, driven by strong performance across all geographies [16] - Tovembra reported a 22% increase in revenue, reflecting continued market leadership in China [18] - In-licensed products grew 27% year-on-year, with the launch of zanadatumab in China [18] Market Data and Key Metrics Changes - The US market generated $685 million with a year-on-year growth of 43% [19] - China revenue totaled $429 million, a 23% increase [19] - Europe contributed $152 million with 87% year-on-year growth [19] - Rest of the world markets grew by 168% driven by market expansions and new launches [19] Company Strategy and Development Direction - The company aims to maintain leadership in the hematology franchise and expand its solid tumor pipeline [5][14] - Plans to run over 20 phase three trials and anticipate more than 10 proof of concept data readouts by 2026 [14] - Focus on serial innovation in CLL to address unmet patient needs across all lines of therapy [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term market leadership for Brukinza despite competitive pricing pressures [17] - The company is optimistic about the prospects for its pipeline and upcoming milestones [14][27] - Management noted that the current guidance reflects known factors, including potential impacts from US tariffs [72] Other Important Information - Gross margin improved to approximately 87% from 85% in the prior quarter, reflecting favorable product mix and production cost efficiencies [20] - Non-GAAP net income reached $253 million, reflecting an increase of $230 million compared to the previous year [22] Q&A Session Summary Question: Update on Brukinza's US net pricing expectations - Management anticipates stable pricing for the remainder of the year and no significant inventory changes [46] Question: Reaction to Bruin CLL 314 data - Management noted that the study did not formally test OR superiority, and emphasized the importance of PFS data [47][48] Question: CDK4 trial timeline - Management updated the timeline for the second line phase three trial to early 2026 to allow for data maturation [52] Question: Market dynamics for CELESTIAL trial - Management expressed optimism about the Xanin plus Sonro combination and its potential market impact [58] Question: Gross margin improvements - Management attributed gross margin improvements to production efficiencies and a favorable product mix [71] Question: Access to Brukinza - Management confirmed that the majority of patients have access to Brukinza, with a successful appeals process for new patients [96] Question: Revenue guidance drivers - Management indicated that the updated revenue guidance reflects confidence in execution across the portfolio [80]

Financial Performance - BeOne reported Q2 2025 revenue of $1.3 billion, a 42% year-over-year increase[13] - BRUKINSA U S revenue reached $684 million, representing a 43% year-over-year growth[16] - TEVIMBRA revenue increased by 22% year-over-year[45] - GAAP earnings per ADS were $0.84, while non-GAAP earnings per ADS were $2.25[13] - GAAP operating cash flow was $264 million, and free cash flow was $220 million[13] BRUKINSA Highlights - BRUKINSA is the U S revenue leader among BTK inhibitors and the fastest-growing brand[15] - BRUKINSA demonstrated an overall response rate (ORR) ranging from 76.3% to 88.4% across different follow-up periods in the ALPINE trial[23] - In the ALPINE trial, BRUKINSA showed progression-free survival (PFS) superiority over ibrutinib in relapsed/refractory CLL patients, with a hazard ratio of 0.66 (95% CI: 0.52, 0.84)[26] Pipeline Development - Registrational filings for Sonro in China for R/R CLL and R/R MCL have been submitted[13] - Phase 3 trials have been initiated for Sonro in combination with CD20 antibody[13] - Global registrational filings for Sonro in R/R MCL are expected in the second half of 2025[13]

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, and 2024, detailing financial performance, position, and cash flows, alongside the company's redomiciliation Condensed Consolidated Statements of Operations Highlights (Q2 & H1 2025 vs 2024) | Financial Metric | Q2 2025 (in thousands) | Q2 2024 (in thousands) | H1 2025 (in thousands) | H1 2024 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | $1,315,300 | $929,166 | $2,432,579 | $1,680,818 | | **Gross Profit** | $1,150,694 | $791,034 | $2,102,971 | $1,417,751 | | **Income (Loss) from Operations** | $87,885 | $(107,161) | $98,987 | $(368,509) | | **Net Income (Loss)** | $94,320 | $(120,405) | $95,590 | $(371,555) | | **Diluted EPS ($)** | $0.06 | $(0.09) | $0.07 | $(0.27) | | **Diluted EPS per ADS ($)** | $0.84 | $(1.15) | $0.85 | $(3.56) | Condensed Consolidated Balance Sheet Highlights | Balance Sheet Item | As of June 30, 2025 (in thousands) | As of Dec 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $4,310,221 | $3,991,593 | | **Total Assets** | $6,298,394 | $5,920,910 | | **Total Current Liabilities** | $2,209,837 | $2,214,899 | | **Total Liabilities** | $2,527,919 | $2,588,688 | | **Total Shareholders' Equity** | $3,770,475 | $3,332,222 | Condensed Consolidated Statements of Cash Flows Highlights (Six Months Ended June 30) | Cash Flow Item | 2025 (in thousands) | 2024 (in thousands) | | :--- | :--- | :--- | | **Net Cash Provided by (Used in) Operating Activities** | $307,680 | $(404,160) | | **Net Cash Used in Investing Activities** | $(188,546) | $(320,863) | | **Net Cash Provided by Financing Activities** | $1,248 | $185,310 | | **Net Increase (Decrease) in Cash** | $147,339 | $(568,053) | - The company redomiciled from the Cayman Islands to Switzerland during the second quarter of 2025, which did not change the accounting basis under U.S. GAAP[22](index=22&type=chunk)[23](index=23&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes strong Q2 2025 performance to significant revenue growth, particularly from BRUKINSA, achieving GAAP profitability and improved operating leverage while maintaining strong liquidity - Key highlights for Q2 2025 include a **42%** increase in total revenues to **$1.3 billion**, a **49%** increase in global BRUKINSA revenues to **$950 million**, and a shift to profitability with GAAP diluted EPS per ADS of **$0.84**[97](index=97&type=chunk) Q2 2025 vs Q2 2024 Net Product Revenue Breakdown (in thousands) | Product | Q2 2025 Revenue | Q2 2024 Revenue | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | BRUKINSA® | $949,840 | $637,399 | $312,441 | 49.0% | | TEVIMBRA® | $193,524 | $158,410 | $35,114 | 22.2% | | XGEVA® | $81,318 | $55,054 | $26,264 | 47.7% | | BLINCYTO® | $25,587 | $19,131 | $6,456 | 33.7% | | KYPROLIS® | $19,416 | $15,936 | $3,480 | 21.8% | | **Total Product Revenue** | **$1,302,076** | **$921,146** | **$380,930** | **41.4%** | - R&D expenses increased **15.5%** to **$524.9 million** in Q2 2025, driven by advancing preclinical programs like Sonrotoclax (BCL2i) into later stages[110](index=110&type=chunk)[112](index=112&type=chunk) - SG&A expenses rose **21.2%** to **$537.9 million** due to global commercial expansion, but decreased as a percentage of product sales from **48.2%** to **41.3%**[115](index=115&type=chunk) Contractual Obligations as of June 30, 2025 (in thousands) | Obligation | Total | Short Term (<1 Year) | Long Term (>1 Year) | | :--- | :--- | :--- | :--- | | Operating lease commitments | $79,054 | $10,608 | $68,446 | | Purchase commitments | $130,087 | $105,910 | $24,177 | | Debt obligations | $954,485 | $808,394 | $146,091 | | Interest on debt | $39,869 | $28,533 | $11,336 | | Co-development funding commitment | $242,916 | $220,869 | $22,047 | | **Total** | **$1,515,180** | **$1,238,641** | **$276,539** | [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces interest rate risk on its floating-rate debt and significant foreign currency exchange risk, particularly from its RMB-denominated operations - The company is exposed to interest rate risk on **$615.4 million** of outstanding floating-rate debt, where a **100-basis point** increase in interest rates would increase annual pre-tax interest expense by approximately **$6.2 million**[159](index=159&type=chunk) - The company faces significant foreign currency exchange risk, particularly from its RMB-denominated operations and deposits, with a hypothetical **10%** appreciation in the U.S. dollar against the RMB resulting in an increased foreign exchange loss of approximately **$11.7 million** as of June 30, 2025[161](index=161&type=chunk) [Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[165](index=165&type=chunk) - There were no material changes in the company's internal control over financial reporting during the quarter ended June 30, 2025[166](index=166&type=chunk) [PART II. OTHER INFORMATION](index=40&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in two significant legal matters: a patent infringement lawsuit from Pharmacyclics regarding BRUKINSA and a trade secret misappropriation lawsuit from AbbVie - In the Pharmacyclics litigation concerning BRUKINSA, the U.S. Patent and Trademark Office (USPTO) issued a Final Written Decision on April 29, 2025, invalidating all challenged claims of the patent in question, with Pharmacyclics' request for review subsequently denied[170](index=170&type=chunk)[171](index=171&type=chunk) - The company is vigorously defending against a lawsuit filed by AbbVie Inc. in September 2024, which alleges misappropriation of trade secrets related to the company's BTK degrader program, including BGB-16673[172](index=172&type=chunk) [Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) This section details comprehensive risks including commercialization, clinical development, regulatory hurdles, financial stability, intellectual property, third-party reliance, operational challenges, and specific risks related to China operations and Swiss redomiciliation - Commercial risks include potential failure of medicines to gain market acceptance, substantial competition from major pharmaceutical companies, and unfavorable pricing or reimbursement regulations from payors like Medicare or China's NRDL[177](index=177&type=chunk)[181](index=181&type=chunk)[186](index=186&type=chunk) - The company faces significant regulatory risks, including the lengthy and unpredictable approval processes of the FDA, NMPA, and EMA, and the potential for clinical trials to fail to demonstrate safety and efficacy[197](index=197&type=chunk)[212](index=212&type=chunk) - Financial risks include a history of significant net losses (**$8.5 billion** accumulated deficit as of June 30, 2025) and the potential need for additional financing to fund operations and development programs[234](index=234&type=chunk)[236](index=236&type=chunk) - Risks related to doing business in China are substantial, including potential intervention by the PRC government, uncertainties in the interpretation and enforcement of Chinese laws (e.g., data security, overseas listings), and limitations on repatriating funds[345](index=345&type=chunk)[346](index=346&type=chunk)[355](index=355&type=chunk) - The recent redomiciliation to Switzerland introduces new risks, including changes in shareholder rights, less flexibility in capital management due to stricter shareholder voting requirements, and potential Swiss withholding taxes on dividends[426](index=426&type=chunk)[427](index=427&type=chunk)[431](index=431&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=98&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company reported no unregistered sales of equity securities, no specific use of proceeds, and no issuer purchases of its equity securities for the period - None reported for the period[433](index=433&type=chunk) [Defaults Upon Senior Securities](index=98&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon its senior securities during the period - None reported for the period[434](index=434&type=chunk) [Mine Safety Disclosures](index=98&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business - Not applicable[435](index=435&type=chunk) [Other Information](index=98&type=section&id=Item%205.%20Other%20Information) This section discloses the adoption and modification of Rule 10b5-1 trading arrangements by two executive officers during the quarter Director and Officer Trading Arrangements (Rule 10b5-1) | Name (Title) | Action (Date) | Nature of Arrangement | Duration | Aggregate Securities | | :--- | :--- | :--- | :--- | :--- | | Chan Lee (SVP, General Counsel) | Adoption (May 14, 2025) | Sale | August 13, 2026 | Up to 36,671 ADSs plus net ADSs from RSU vestings | | Dr. Xiaobin Wu (President, COO) | Modification (May 14, 2025) | Sale | August 13, 2026 | Up to 89,794 ADSs | [Exhibits](index=99&type=section&id=Item%206.%20Exhibits) This section provides an index of all exhibits filed with the 10-Q, including corporate governance documents, executive agreements, and required certifications - Key exhibits filed include: - 3.1: Articles of Association of BeOne Medicines Ltd - 10.1-10.5: Executive Employment Agreements for key officers - 10.18: Fifth Amended and Restated 2018 Employee Share Purchase Plan - 31.1 & 31.2: Certifications of Principal Executive Officer and Principal Financial Officer[441](index=441&type=chunk)[442](index=442&type=chunk)[443](index=443&type=chunk)

R&D Strategy and Pipeline - BeiGene's R&D strategy focuses on developing a deep and impactful portfolio, executing fast-to-PoC for value maximization, initiating combination therapies early, and advancing only transformative medicines to late-stage development[18] - BeiGene has an extensive investment in innovative platforms, supporting a robust preclinical pipeline of 69 programs, with 51% biologics and 43% small molecules[19, 20] - BeiGene is transforming its pipeline with a focus on heme leadership and solid tumor diversification, expecting POC data readouts for many NMEs in the next 1-2 years[21] Solid Tumor Programs - BGB-43395 (CDK4i) is undergoing dose escalation in monotherapy and in combination with endocrine therapy (ET) in breast cancer patients[34] - Preliminary data from the BGB-43395-101 study shows a manageable safety profile, with diarrhea and nausea being the most commonly reported AEs[28] - BGB-43395 exhibits rapid absorption with a median Tmax of approximately 2 hours, and exposures increased approximately dose proportionately[42] Hematology Programs - Brukinsa (Zanubrutinib) - Brukinsa has demonstrated sustained PFS superiority over Ibrutinib in the ALPINE H2H study with 42.5 months follow-up, with a HR of 0.68 (95% CI: 0.54, 0.84)[74] - In the ALPINE study, Zanubrutinib showed sustained superiority and risk reduction in the TP53/Del17p population, with a HR of 0.51 (95% CI: 0.33, 0.78)[78, 80] - In the SEQUOIA study, Zanubrutinib demonstrated a sustained PFS benefit in treatment-naive unfit CLL/SLL patients, with a 71% reduction in risk of progression or death[88, 96] Hematology Programs - Sonrotoclax - In a Phase 1/1b study, Sonrotoclax combined with Zanubrutinib as frontline treatment for CLL demonstrated high MRD clearance rates, with 90% achieving uMRD by week 48 in the 320mg cohort[68, 122] - The CELESTIAL-TNCLL trial is an ongoing Phase 3 study assessing Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab for treatment-naive CLL[68, 142] Hematology Programs - BTK CDAC (BGB-16673) - In a Phase 1 study, the BTK degrader BGB-16673 showed an ORR of 77.6% in heavily pre-treated R/R CLL/SLL patients, with an ORR of 93.8% at 200 mg[169, 181] - BGB-16673 demonstrated promising activity in patients with Richter Transformation, with an ORR of 58.3%[175, 180] - BGB-16673 also showed high overall response rates and VGPRs in R/R WM patients, with an ORR of 81.5%[190, 193]

Summary of BeiGene (BGNE) Update / Briefing June 26, 2025 Company Overview - **Company Name**: B1 Medicines (formerly BeiGene) - **Focus**: Oncology, specifically in the development of innovative cancer treatments Key Points and Arguments 1. **Mission and Vision**: B1 Medicines aims to transform the R&D process in oncology, making medicines more affordable and accessible while providing superior returns to investors [6][10][11] 2. **Commitment to Oncology**: The company emphasizes its dedication to fighting cancer, especially as some competitors shift focus to other therapeutic areas [8][9] 3. **R&D Model**: B1 has developed a unique R&D model that prioritizes quality, speed, and cost efficiency, allowing for a significant increase in the number of new molecule entities entering clinical trials [25][26][27] 4. **Clinical Development**: The company has built a global clinical development team of over 3,700 professionals, enabling it to conduct trials without relying on Contract Research Organizations (CROs), thus reducing costs and improving quality [42][44] 5. **Pipeline Expansion**: B1 has a robust pipeline with 96 ongoing trials across various phases and modalities, reflecting its commitment to advancing transformative medicines [39][40] 6. **Hematology Franchise**: The company has established a strong hematology franchise with three key medicines and aims to expand its leadership in Chronic Lymphocytic Leukemia (CLL) and beyond [19][56] 7. **Innovative Treatments**: B1 is developing next-generation BCL-2 inhibitors, such as Sonorotoclax, which aim to address the limitations of existing treatments like Venetoclax [67][72] 8. **Combination Therapies**: The combination of Sonorotoclax with Zanubrutinib shows promising results in achieving high rates of undetectable measurable residual disease (MRD) and favorable safety profiles [88][90] Additional Important Content 1. **Patient Impact**: B1 has already helped 1.7 million patients and their families in the fight against cancer, showcasing its commitment to patient care [15][16] 2. **Investment in Technology**: The company has made substantial investments in various modalities, including protein degraders and antibody-drug conjugates, to enhance its drug development capabilities [26][29][33] 3. **Regulatory Success**: Burkynza, a key product, has achieved significant market penetration and has been approved in 75 markets, demonstrating its efficacy and safety compared to competitors [59][62] 4. **Market Opportunity**: Despite advancements in CLL treatment, there remains a considerable unmet medical need, particularly for fixed-duration treatments, which B1 aims to address with its innovative therapies [56][57][71] This summary encapsulates the core messages and strategic direction of B1 Medicines as presented in the briefing, highlighting its commitment to innovation in oncology and the development of impactful treatments for cancer patients.

Company Strategy & R&D Model - BeOne aims to transform cancer care globally by delivering innovative medicines faster, more equitably, and affordably[12, 16] - The company's R&D model leverages a prolific research organization, global manufacturing, efficient clinical development, and global commercial access to achieve superior R&D returns[25] - BeOne focuses on delivering high-quality innovation by designing superior molecules with exceptional profiles and halting programs that don't meet high standards; over 60 preclinical programs have been terminated in the past 3.5 years[30, 32] - The company is building a deep pipeline, aiming to deliver 8-10 highly differentiated new molecular entities (NMEs) into the clinic in each focused disease area in the next 3-6 years[42] Hematology Portfolio & CLL - BeOne is positioned to address unmet needs in CLL with a wholly-owned portfolio including BRUKINSA, sonrotoclax, and BTK CDAC[93] - BRUKINSA is the only BTKi to demonstrate PFS superiority over ibrutinib in a head-to-head Phase 3 R/R CLL trial[100] - In treatment-naive CLL/SLL patients, 60-month PFS with zanubrutinib was 72.2% in patients with del(17p), similar to 75.8% in patients without del(17p)[105] - Sonrotoclax + zanubrutinib achieved fast and deep responses in TN CLL/SLL, with 84% uMRD at week 48 in the 160mg dose group and 92% uMRD in the 320mg dose group[133] Solid Tumor Portfolio - The global CDK4/6i market is large and growing, estimated at approximately $13 billion[244] - BG-C9074 (B7-H4 ADC) demonstrated a confirmed ORR of 24% and an unconfirmed ORR of 29% among 68 efficacy-evaluable patients, with activity at 6mg/kg Q3W showing a confirmed ORR of 43% and an unconfirmed ORR of 48%[296] - BGB-58067 (PRMT5i) showed early responses at the second dose level in a Phase 1 study, with three objective responses observed in histologically distinct tumor types[331]

Core Insights - Zymeworks Inc. is advancing its oncology programs with multiple presentations scheduled at major medical conferences, including ASCO and ESMO, highlighting its commitment to developing novel biotherapeutics for difficult-to-treat diseases [1][3][10] Oncology Programs - The company is particularly focused on zanidatamab, which is being presented at ASCO, showcasing long-term outcomes and survival data in HER2-positive gastroesophageal cancer [2][4][6] - Zymeworks' proprietary Azymetric™ platform is emphasized for its ability to develop clinically validated therapeutic antibodies, with zanidatamab being a key example [6][14] Upcoming Presentations - Zymeworks and its partners will present multiple abstracts at the ASCO Annual Meeting from May 31 to June 4, 2025, in Chicago, IL [3] - The ESMO Gynaecological Cancers Congress will also feature a trial-in-progress poster for ZW191, scheduled for June 19-21, 2025, in Vienna, Austria [10] Product Details - Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody that has received accelerated approval from the FDA for treating advanced HER2-positive biliary tract cancer [18][34] - ZW171 is a bispecific antibody targeting mesothelin and CD3, designed to enhance T cell-mediated tumor cell killing, with promising preclinical data supporting its efficacy [15][34] - ZW191 is an antibody-drug conjugate targeting folate receptor-α, showing strong activity across various cancer models, including those with low levels of the target [16][17] Clinical Development - The company is actively recruiting for Phase 1 studies of ZW171 and ZW191, with plans for an investigational new drug application for ZW251 in mid-2025 [34] - Zymeworks has established partnerships with BeiGene and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in different territories [33][34]